Use left and right arrow keys to navigate between menu items.

Use escape to exit the menu.

With an aggressive new strain spreading across the country, this year’s flu season has been marked by record-high hospitalizations and reportedly intense symptoms.

As people look for ways to contain the spread, new research has found that a few simple factors can greatly reduce transmission.

Researchers from the University of Maryland Schools of Public Health and Engineering in College Park and the School of Medicine in Baltimore studied influenza spread by placing flu-positive college students in a hotel room with healthy middle-aged adult volunteers.

FLU HOSPITALIZATIONS HIT ALL-TIME WEEKLY HIGH IN DENSELY POPULATED STATE, OFFICIALS WARN

The study, published in the journal PLOS Pathogens, is reportedly the first clinical trial investigating how the flu spreads from naturally infected people to uninfected people, according to a press release.

The participants, including 11 healthy volunteers, lived on a quarantined floor of a Baltimore-area hotel for two weeks. During that time, they simulated interactions, including having conversations, doing physical activities like yoga, and passing around objects like pens and tablets from infected people to the rest of the group.

Researchers monitored the participant’s symptoms, performed daily nasal swabs, and collected saliva and blood samples to test for antibodies, the release stated.

The study also measured the “viral exposure” in the volunteers’ breathing air and ambient air in the activity room. The exhaled breath of the participants was measured by a machine called the Gesundheit II, invented by researcher Dr. Donald Milton and colleagues at Harvard T.H. Chan School of Public Health.

COULD DENTAL FLOSS BE THE NEXT VACCINE METHOD? SCIENTISTS SAY IT COULD WORK

At the end of the experiment, none of the healthy individuals had become infected with the flu due to a variety of factors. This included a lack of coughing, as the infected students were holding “a lot of virus in their noses” and only small amounts were “expelled into the air,” the researchers noted.

“Our data suggests key things that increase the likelihood of flu transmission — coughing is a major one,” Dr. Jianyu Lai, post-doctoral research scientist and the study’s lead data analyst and report writer, shared in a statement.

CLICK HERE FOR MORE HEALTH STORIES

The other factor was ventilation and air movement, as the air in the study room was “continually mixed rapidly by a heater and dehumidifier, and so the small amounts of virus in the air were diluted,” Lai pointed out.

The researcher added that middle-aged adults are “usually less susceptible” to influenza than younger adults.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Most researchers assume that airborne transmission is a major factor of disease spread, according to Dr. Donald Milton, professor at SPH’s Department of Global, Environmental and Occupational Health and a global infectious disease aerobiology expert.

“At this time of year, it seems like everyone is catching the flu virus, and yet our study showed no transmission,” he said in the same press release. “What does this say about how flu spreads and how to stop outbreaks?”

Milton, who was reportedly among the first experts to identify how to stop the spread of COVID-19, noted that findings from these types of trials are essential to updating international infection-control guidelines.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“Being up close, face-to-face with other people indoors where the air isn’t moving much, seems to be the most risky thing — and it’s something we all tend to do a lot,” he said.

“At this time of year, it seems like everyone is catching the flu virus, and yet our study showed no transmission.”

Advertisement

“Our results suggest that portable air purifiers that stir up the air, as well as clean it, could be a big help,” Milton suggested. “But if you are really close and someone is coughing, the best way to stay safe is to wear a mask, especially the N95.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Approximately 11 million flu illnesses and about 5,000 deaths have occurred so far in the 2025-2026 influenza season, according to CDC data. A large share of the current flu cases are caused by the new influenza A subclade K variant.

GLP-1 has become a popular buzzword in the weight-loss community — but now some are touting “GLP-3s,” claiming they are taking obesity medications to the next level.

GLP-1 (glucagon-like peptide-1) medications work by mimicking a naturally occurring hormone in the body that helps regulate blood sugar and appetite.

The informal term “GLP-3” refers to a new triple-agonist drug that targets three hormones: GLP-1, GIP (glucose-dependent insulinotropic polypeptide, another naturally occurring hormone released by the gut after eating) and glucagon receptors. The most advanced example is retatrutide by Eli Lilly, according to clinical trial outcomes.

OBESITY EXPERT REVEALS THE BEST WAY TO DECIDE IF GLP-1S ARE RIGHT FOR YOU

The New England Journal of Medicine published results from a 2023 phase 2 retatrutide trial for obesity, revealing “substantial reductions in body weight” after 48 weeks of treatment.

A 12 mg once-weekly injection led to a 24.2% weight reduction, and participants continued to drop pounds after the 48-week trial period.

Side effects were reportedly similar to GLP-1 medications, most commonly including gastrointestinal complications like nausea, vomiting and diarrhea. Heart rate increases were noted, depending on the dose.

How it’s different

Retatrutide mimics three natural hormones found in the body, compared to GLP-1s that simulate just one hormone, according to a report by GoodRx pharmacists.

GIP and GLP-1 hormones signal the pancreas to release insulin after eating, while slowing digestion to help initiate feelings of fullness.

NEW WEGOVY PILL OFFERS NEEDLE-FREE WEIGHT LOSS — BUT MAY NOT WORK FOR EVERYONE

These hormones target the area of the brain that regulates appetite and influences food cravings, the report noted.

The third hormone, glucagon, speeds up metabolism and helps the body break down fat cells for energy. That hormone also tells the liver to make new sugar, which is kept in check by GIP and GLP-1 activity, preventing blood sugar spikes.

“This added metabolism boost can add to and complement GIP’s and GLP-1’s actions. And that’s why it seems to provide significant weight loss,” the GoodRx website states. “If approved, retatrutide will be the first in a new class of medications.”

Eli Lilly announced results from its phase 3 trial TRIUMPH-4 in December, testing retatrutide’s effect on weight loss and other health conditions.

“We believe retatrutide could become an important option for patients with significant weight loss needs and certain complications.”

Participants with obesity and knee arthritis who took a 12-mg dose of retatrutide saw an average weight loss of 71.8 lbs (28.7%) at 68 weeks.

“For retatrutide, the findings from TRIUMPH-4 are encouraging, and with seven additional phase 3 readouts expected in 2026, we believe retatrutide could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis,” a Lilly spokesperson said in a statement to Fox News Digital. 

CLICK HERE FOR MORE HEALTH STORIES

The drug also reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores by an average of 75.8%, marking “significant improvements” in comfort level and physical function.

More than one in eight patients reported being “completely free” from knee pain at the end of the trial, according to a press release from Lilly.

Seven additional phase 3 trials for retatrutide are expected to wrap up in 2026. The drug could see FDA approval in 2027, according to GoodRx.

The Lilly spokesperson noted that there have been no studies comparing retatrutide to GLP-1 treatments due to “differences in study design and patient populations.”

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Despite limited data availability on the drug, the medication could also be applied to treat other conditions like type 2 diabetes, kidney disease, cardiovascular risk reduction and metabolic dysfunction, according to GoodRx and other experts.

Fox News senior medical analyst Dr. Marc Siegel noted that Lilly’s Zepbound and Mounjaro already target two metabolic pathways — GLP-1 and GIP — which work together to promote weight loss, reduce hunger and inflammation, improve insulin function and slow digestion.

The doctor confirmed that the new drug, with its third receptor agonist, will further decrease hunger while increasing the feeling of fullness.

“The weight loss in clinical trials is even more substantial, and the most likely reason that it decreases orthopedic problems is because of the weight loss — less stress on the joints and the decreased inflammation,” Siegel added.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The most common side effect of GLP-3s is gastrointestinal symptoms, the doctor confirmed. Rarer side effects may include pancreatitis, gallstones and heart arrhythmia.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Philip Rabito, M.D., a specialist in endocrinology, weight loss and wellness in New York City, shared in an interview with Fox News Digital that this new class of weight-loss drugs is positioned to “approach bariatric surgery level outcomes” — although it doesn’t come without risks.

“The novel glucagon‑agonist component introduces less‑understood long‑term safety considerations, so it is imperative that patients are followed closely by healthcare professionals experienced with this class of medicines, with cautious, stepwise use, despite the impressive efficacy,” he cautioned.